Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis

Basic Research in Cardiology

Volumn 104, Issue 3, 2009, Pages 285-294

  Gebhard, Catherine ^a,b   Stämpfli, Simon F ^a,b   Gebhard, Caroline E ^a   Akhmedov, Alexander ^a   Breitenstein, Alexander ^a,b   Camici, Giovanni G ^a   Holy, Erik W ^a,b   Lüscher, Thomas F ^a,b   Tanner, Felix C ^a,b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Arterial thrombosis; Photochemical injury; Phytosterol; Tissue factor

Indexed keywords

GUGGULSTERONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PLASMINOGEN ACTIVATOR INHIBITOR 1; STRESS ACTIVATED PROTEIN KINASE; THROMBOPLASTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERY THROMBOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOTOOXIDATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; THROMBOGENESIS; THROMBOSIS PREVENTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; CAROTID ARTERY THROMBOSIS; CELLS, CULTURED; ENDOTHELIAL CELLS; ENZYME ACTIVATION; GENE EXPRESSION; HUMANS; MAP KINASE KINASE 4; MICE; MUSCLE, SMOOTH, VASCULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHYTOSTEROLS; PREGNENEDIONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THROMBOPLASTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64949136432     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-008-0757-5     Document Type: Article

References (37)

1. Agarwal RC, Singh SP, Saran RK, Das SK, Sinha N, Asthana OP, Gupta PP, Nityanand S, Dhawan BN, Agarwal SS (1986) Clinical trial of gugulipid - a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res 84:626
2. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F (1988) Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 59:535
3. Baldwa VS, Bhasin V, Ranka PC, Mathur KM (1981) Effects of Commiphora mukul (Guggul) in experimentally induced hyperlipemia and atherosclerosis. J Assoc Physicians India 29:13
4. Bishop-Bailey D (2004) FXR as a novel therapeutic target for vascular disease. Drug News Perspect 17:499
5. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC (2006) Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: A potential treatment strategy for drug-eluting stents. Circulation 114:1512-1521
6. Crawley JT, Lane DA (2008) The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 28:233
7. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP (2005) Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 105:192
8. Eitzman DT, Bodary PF, Shen Y, Khairallah CG, Wild SR, Abe A, Shaffer-Hartman J, Shayman JA (2003) Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis. J Am Soc Nephrol 14:298
9. Gaur SPS, Garg RK, Kar AM, Purohit JK, Gupta A (1997) Gugulipd,a new hypolipidaemic agent, in patients of acute ischaemic stroke: Effect on clinical outcome, platelet function and serum lipids. Asia Pac J Pharmacol 12:65-69
10. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2:3
11. He F, Li J, Mu Y, Kuruba R, Ma Z, Wilson A, Alber S, Jiang Y, Stevens T, Watkins S, Pitt B, Xie W, Li S (2006) Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ Res 98:192
12. Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG (1996) Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation 94:2057
13. Kalsch T, Elmas E, Nguyen XD, Suvajac N, Kluter H, Borggrefe M, Dempfle CE (2007) Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 102:460
14. Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A, Aggarwal BB (2007) Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 7:344
15. Langer HF, Gawaz M (2008) Platelets in regenerative medicine. Basic Res Cardiol 103:299
16. Levi M, van der Poll T, Buller HR (2004) Bidirectional relation between inflammation and coagulation. Circulation 109:2698
17. Li YT, Swales KE, Thomas GJ, Warner TD, Bishop-Bailey D (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27:2606
18. Luyendyk JP, Piper JD, Tencati M, Reddy KV, Holscher T, Zhang R, Luchoomun J, Chen X, Min W, Kunsch C, Mackman N (2007) A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases. Arterioscler Thromb Vasc Biol 27:1857
19. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sutsch G, Roffi M, Neidhart M, Eberli FR, Tanner FC, Gobbi S, von Eckardstein A, Luscher TF (2005) Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: Locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 111:1355
20. Ott I, Michaelis C, Schuermann M, Steppich B, Seitz I, Dewerchin M, Zohlnhofer D, Wessely R, Rudelius M, Schomig A, Carmeliet P (2005) Vascular remodeling in mice lacking the cytoplasmic domain of tissue factor. Circ Res 97:293
21. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, De Filippis EA, Buongiorno A, Pellegrini G, Capani F, Consoli A (2001) Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol 38:71
22. Shishodia S, Aggarwal BB (2004) Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279:47148
23. Singh RB, Niaz MA, Ghosh S (1994) Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 8:659
24. Stahli BE, Camici GG, Steffel J, Akhmedov A, Shojaati K, Graber M, Luscher TF, Tanner FC (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99:149
25. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC (2005) Histamine induces tissue factor expression: Implications for acute coronary syndromes. Circulation 112:341
26. Steffel J, Hermann M, Greutert H, Gay S, Luscher TF, Ruschitzka F, Tanner FC (2005) Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 111:1685
27. Steffel J, Latini RA, Akhmedov A, Zimmermann D, Zimmerling P, Luscher TF, Tanner FC (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 112:2002
28. Steffel J, Luscher TF, Tanner FC (2006) Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation 113:722
29. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, Rader DJ (2003) Guggulipid for the treatment of hypercholesterolemia: A randomized controlled trial. JAMA 290:765
30. Tilley R, Mackman N (2006) Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost 32:5
31. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ (1997) Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95:594
32. True AL, Olive M, Boehm M, San H, Westrick RJ, Raghavachari N, Xu X, Lynn EG, Sack MN, Munson PJ, Gladwin MT, Nabel EG (2007) Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res 101:893
33. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296:1703
34. Urizar NL, Moore DD (2003) GUGULIPID: A natural cholesterol-lowering agent. Annu Rev Nutr 23:303
35. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP (2008) Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 47:3
36. Verma N, Singh SK, Gupta RC (1999) Pharmacokinetics of guggulsterone after intravenous and oral administration in rats. Pharm Pharmacol Comm 5:349
37. Wang X, Greilberger J, Ledinski G, Kager G, Paigen B, Jurgens G (2004) The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL. Atherosclerosis 172:239